What Does Bethesda III Mean?

Bethesda III is a cytology result. Cytology is the study of loose cells, rather than a whole piece of tissue. Your report may spell the category out as atypia of undetermined significance. That phrase is often shortened to AUS. Some reports add follicular lesion of undetermined significance, or FLUS. Atypia means the cells look a little odd. Undetermined significance means no one can yet say what the oddness means.

The number is not a stage. It is not a tumor grade. It says the sample could be read, but the cells sat in a gray zone.

Thyroid needle samples get sorted into six groups. Each group carries a rough chance that surgery will find cancer. Reviews hosted by the National Institutes of Health list them this way.

• I, nondiagnostic or unsatisfactory: 5-10%.
• II, benign: 0-3%.
• III, atypia of undetermined significance: 6-18%.
• IV, follicular neoplasm, or suspicious for one: 10-40%.
• V, suspicious for malignancy: 45-60%.
• VI, malignant: 94-96%.

One footnote shifts those figures. NIFTP stands for noninvasive follicular thyroid neoplasm with papillary-like nuclear features. It is a walled-off growth that is no longer counted as cancer. If a lab does count NIFTP as cancer, the same table reads 10-30% for III, 25-40% for IV, 50-75% for V, and 97-99% for VI. A second NIH-hosted review gives the Bethesda III risk as 10 to 30%.

So the honest answer is a band, not one figure. Either way, III is the third rung on a six-rung ladder. Most Bethesda III nodules turn out not to be cancer. A real minority do.

The sample came from a fine-needle aspiration, or FNA. A thin needle draws a few drops of cells from the thyroid nodule. Ultrasound usually guides the tip. The drops are smeared on slides, stained, and read under a microscope.

That is a tiny sample of a lump far bigger than the needle. A needle can miss the odd part, or it can hit only the odd part. This is sampling error, and it is a main reason the gray zone exists at all. Two skilled pathologists can also read one slide and land on different categories. That is interobserver variation, and Bethesda III is where it shows up most.

Centers handle this result differently. Three routes are common.

Repeat the needle test. Some centers redo the FNA after 6 to 12 weeks. A second reading gives a clear answer in only about 40% of cases, so this is no magic fix.

Send cells for molecular testing. This reads the genes inside the cells rather than just their shape.

Remove half the thyroid. That operation is a lobectomy. It is both treatment and the final answer, because the whole nodule can then be examined.

Your ultrasound picture also steers the choice. A nodule with worrying features on the scan pushes toward action. A plain, soft-looking one supports watching.

Molecular tests look for gene changes linked to thyroid cancer. Two are widely used, and NIH-hosted reviews report their measured performance.

ThyroSeq V3 uses targeted sequencing of 112 cancer related genes. It has a sensitivity of 94% and a specificity of 82%.

Afirma GSC reads RNA instead. It has a sensitivity of 96%, specificity of 68%.

Sensitivity is the share of true cancers a test catches. Specificity is the share of harmless nodules it correctly clears. High sensitivity means a negative result is fairly reassuring. Lower specificity means a positive result still needs proof from surgery. Two-step methods such as ThyGeNEXT with ThyraMIR are in use as well.

The practical effect is that fewer people need an operation just to learn the answer. Reviews credit these panels with lowering the need for diagnostic lobectomy.

A Bethesda category is a probability statement. It is not a diagnosis. The wording does not say you have cancer, and it does not say you are in the clear. Nobody can tell you which side of the range you sit on from the category alone.

The result also cannot name the tumor type, or say whether anything has spread. Those answers need tissue, not loose cells.

The percentages move with the reader, the lab, and the edition of the manual in use. If your report quotes a figure, ask whether it comes from this lab's own records or from a published table.

• Which subtype of Bethesda III did my sample fall into?
• What rate of cancer does this lab see in its own Bethesda III cases?
• Is enough material left for molecular testing, or would I need another needle?
• What did the ultrasound show, and does it raise or lower the concern?
• If we wait and repeat, how long should we wait, and what would make us act sooner?
• If we operate, would that be half the thyroid or all of it, and why?
• Is a second pathologist's reading of the same slide worth requesting?

The National Cancer Institute notes that thyroid biopsy samples should be checked by a pathologist who has experience diagnosing thyroid cancer. That advice carries real weight in the gray zone. Category III is defined by cells that fall short of a clear call, so the reader's judgment does more work here than in a plainly benign or plainly malignant case.

This is also why a formal second review is a reasonable request. You are not questioning anyone's skill. You are asking a borderline slide to be read twice.

It helps to know that category I, the nondiagnostic group, is a different problem. There the sample simply did not contain enough usable cells, and the needle test is usually repeated in 4 to 6 weeks. Category III means the cells were there and readable. They just did not settle the question.

Start with Pathology Reports, Biopsy, Imaging Tests, and Getting a Second Opinion.

• Endotext (NIH National Library of Medicine) — Fine-Needle Aspiration of the Thyroid Gland.
• StatPearls (NIH National Library of Medicine) — Thyroid Nodule.
• Endotext (NIH National Library of Medicine) — Bethesda System and Estimated Risk of Malignancy table.
• National Cancer Institute — Thyroid Cancer Treatment (PDQ) Patient Version.